financetom
Business
financetom
/
Business
/
Here's How This AI CEO Just Doubled His Net Worth To $10 Billion—In Just Only 12 Days
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Here's How This AI CEO Just Doubled His Net Worth To $10 Billion—In Just Only 12 Days
Jun 28, 2025 10:32 AM

Michael Intrator, the CEO of AI startup CoreWeave, has seen his net worth double to a whopping $10 billion in a mere 12 days. This rapid wealth accumulation is unprecedented in the tech industry.

What Happened: CoreWeave’s stock has skyrocketed by nearly 300% in the last two months. This followed a rather unimpressive initial public offering (IPO) in March.

The stock’s surge has greatly enriched its shareholders, including Intrator, a 56-year-old former hedge fund manager.

Bloomberg notes that Intrator’s net worth has soared from $5 billion to $10 billion in less than two weeks. This is an extraordinary achievement, given that it usually takes a billionaire over three years to double their wealth.

Despite CoreWeave’s initial lackluster performance on the stock market, Intrator remained steadfast in his belief in the company’s potential to “generate enormous value.”

Also Read: Michael Saylor Called Scaramucci From a Yacht and It Changed the Ending of His Book

CoreWeave’s other co-founders have also seen their wealth grow significantly. Bloomberg reports that the company’s chief strategy officer, Brian Venturo, is now worth $6.4 billion, while chief development officer, Brannin McBee, is worth $4.7 billion, reports Fortune.

The company’s success can be attributed to securing major tech companies as clients and partners, including Nvidia, OpenAI, and Microsoft. 

Interestingly, all three founders come from finance backgrounds, not tech, highlighting that breaking into AI does not necessarily require a tech background.

Why It Matters: CoreWeave’s success story is a testament to the immense potential of AI technology and its ability to generate wealth rapidly.

The company’s ability to secure partnerships with major tech companies, despite its founders’ non-tech backgrounds, underscores the importance of strategic alliances and business acumen in the tech industry.

This could potentially inspire more finance professionals to venture into the tech industry, particularly AI, thereby fostering greater diversity and innovation in the sector.

Read Next

Telegram CEO Pavel Durov To Leave His $13.9 Billion Fortune to His 100+ Children

Image: Shutterstock/Odu Mazza

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Westaim Completes US$79-Million Sale of Remaining Interest in Skyward Specialty Insurance
Westaim Completes US$79-Million Sale of Remaining Interest in Skyward Specialty Insurance
Sep 11, 2024
05:02 PM EDT, 09/10/2024 (MT Newswires) -- Westaim ( WEDXF ) after trade Tuesday said it sold all its remaining 1.91-million shares in Skyward Specialty Insurance Group. The investment-holding company said proceeds, less commissions, were approximately US$79 million. Westaim's ( WEDXF ) remaining investments include significant interests in Arena and the Arena FINCOs. The company's shares closed down $0.04 to...
Abercrombie & Fitch Insider Sold Shares Worth $2,501,264, According to a Recent SEC Filing
Abercrombie & Fitch Insider Sold Shares Worth $2,501,264, According to a Recent SEC Filing
Sep 11, 2024
05:10 PM EDT, 09/10/2024 (MT Newswires) -- Samir Desai, Executive Vice President, Chief Digital & Technology Officer, on September 06, 2024, sold 19,041 shares in Abercrombie & Fitch ( ANF ) for $2,501,264. Following the Form 4 filing with the SEC, Desai has control over a total of 27,985 shares of the company, with 27,985 shares held directly. SEC Filing:...
BridgeBio to stop development of therapy for genetic disorder
BridgeBio to stop development of therapy for genetic disorder
Sep 11, 2024
Sept 10 (Reuters) - BridgeBio Pharma ( BBIO ) said on Tuesday it will stop development of its experimental therapy for a genetic disease that affects the adrenaline-producing gland. The drugmaker said the results of its early-to-mid stage study testing the therapy did not meet the threshold to warrant additional capital investment. (Reporting by Puyaan Singh; Editing by Shinjini Ganguli)...
Sentinelone Insider Sold Shares Worth $1,140,682, According to a Recent SEC Filing
Sentinelone Insider Sold Shares Worth $1,140,682, According to a Recent SEC Filing
Sep 11, 2024
05:00 PM EDT, 09/10/2024 (MT Newswires) -- Ric Smith, Chief Product & Technology Officer, on September 06, 2024, sold 51,052 shares in Sentinelone ( S ) for $1,140,682. Following the Form 4 filing with the SEC, Smith has control over a total of 585,647 shares of the company, with 585,647 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1583708/000158370824000078/xslF345X05/wk-form4_1726001520.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved